See more : Japan Elevator Service Holdings Co.,Ltd. (6544.T) Income Statement Analysis – Financial Results
Complete financial analysis of Lexicon Pharmaceuticals, Inc. (LXRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lexicon Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Prime US REIT (OXMU.SI) Income Statement Analysis – Financial Results
- C2E Energy, Inc. (OOGI) Income Statement Analysis – Financial Results
- Beijing Capital Eco-environment Protection Group Co.,ltd. (600008.SS) Income Statement Analysis – Financial Results
- COSCO SHIPPING Technology Co., Ltd. (002401.SZ) Income Statement Analysis – Financial Results
- Saxlund Group AB (publ) (SAXG.ST) Income Statement Analysis – Financial Results
Lexicon Pharmaceuticals, Inc. (LXRX)
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.20M | 139.00K | 298.00K | 24.00M | 322.07M | 63.21M | 90.34M | 83.34M | 130.01M | 22.85M | 2.22M | 1.09M | 1.85M | 4.91M | 10.70M | 32.32M | 50.12M | 72.80M | 75.68M | 61.74M | 42.84M | 35.20M | 305.58M | 14.46M | 4.70M |
| Cost of Revenue | 85.00K | 427.00K | 55.05M | 1.93M | 3.23M | 2.49M | 1.90M | 163.97M | 95.19M | 89.28M | 89.68M | 82.57M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.62M | -2.00M |
| Gross Profit | 1.12M | -288.00K | -54.75M | 22.07M | 318.84M | 60.72M | 88.44M | -80.64M | 34.83M | -66.43M | -87.46M | -81.49M | 1.85M | 4.91M | 10.70M | 32.32M | 50.12M | 72.80M | 75.68M | 61.74M | 42.84M | 35.20M | 305.58M | 17.08M | 6.70M |
| Gross Profit Ratio | 92.94% | -207.19% | -18,371.81% | 91.96% | 99.00% | 96.06% | 97.90% | -96.76% | 26.79% | -290.65% | -3,936.09% | -7,482.55% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 118.13% | 142.55% |
| Research & Development | 58.89M | 52.82M | 55.05M | 153.62M | 91.92M | 100.24M | 156.81M | 178.15M | 95.19M | 89.28M | 89.68M | 82.57M | 91.83M | 75.35M | 81.24M | 108.58M | 104.33M | 106.70M | 93.63M | 90.59M | 82.20M | 74.86M | 53.36M | 31.65M | 14.60M |
| General & Administrative | 0.00 | 48.08M | 0.00 | 0.00 | 0.00 | 63.75M | 66.20M | 43.04M | 23.84M | 19.41M | 17.12M | 17.04M | 17.35M | 22.57M | 19.42M | 20.28M | 20.74M | 21.33M | 0.00 | 0.00 | 0.00 | 0.00 | 20.86M | 18.29M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 113.98M | 48.08M | 32.34M | 47.23M | 56.84M | 63.75M | 66.20M | 43.04M | 23.84M | 19.41M | 17.12M | 17.04M | 17.35M | 22.57M | 19.42M | 20.28M | 20.74M | 21.33M | 18.17M | 18.61M | 23.23M | 23.23M | 20.86M | 18.29M | 2.90M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 1.60M | 28.64M | 0.00 | 1.95M | 2.29M | 572.00K | 2.26M | 59.00K | 105.00K | 24.12M | 2.71M | 0.00 | 20.28M | 20.74M | 21.33M | 18.17M | 18.61M | 23.23M | 23.23M | 275.00M | 2.62M | 4.90M |
| Operating Expenses | 172.87M | 100.90M | 87.39M | 200.85M | 148.76M | 164.00M | 223.02M | 221.20M | 119.02M | 108.69M | 106.80M | 99.62M | 115.94M | 100.63M | 100.66M | 128.86M | 125.07M | 128.03M | 111.80M | 109.19M | 105.43M | 98.09M | 349.22M | 52.56M | 19.50M |
| Cost & Expenses | 172.95M | 100.90M | 87.39M | 202.78M | 151.99M | 166.49M | 224.92M | 221.20M | 119.02M | 108.69M | 106.80M | 99.62M | 115.94M | 100.63M | 100.66M | 128.86M | 125.07M | 128.03M | 111.80M | 109.19M | 105.43M | 98.09M | 349.22M | 49.94M | 17.50M |
| Interest Income | 7.73M | 1.60M | 134.00K | 2.77M | 3.35M | 3.51M | 1.95M | 2.29M | 572.00K | 2.26M | 157.00K | 213.00K | 255.00K | 519.00K | 880.00K | 5.76M | 7.29M | 3.65M | 2.65M | 1.64M | 1.80M | 3.23M | 8.78M | 9.90M | 0.00 |
| Interest Expense | 13.10M | 2.78M | 802.00K | 14.54M | 20.68M | 20.78M | 6.98M | 6.57M | 6.72M | 2.25M | 1.97M | 2.11M | 2.53M | 2.72M | 2.97M | 2.69M | 2.77M | 3.25M | 3.28M | 2.66M | 325.00K | 7.00K | 314.00K | 422.04K | 0.00 |
| Depreciation & Amortization | 554.00K | 427.00K | 292.00K | 2.93M | 3.65M | 3.68M | 3.40M | 2.06M | 727.00K | 1.93M | 2.86M | 4.19M | 4.89M | 5.39M | 6.16M | 10.07M | 10.42M | 11.20M | 11.64M | 12.87M | 21.53M | 20.58M | 16.55M | 2.62M | 2.00M |
| EBITDA | -163.46M | -98.74M | -86.66M | -41.10M | 173.74M | -96.09M | -125.27M | -125.82M | 11.72M | -96.18M | -99.29M | -103.91M | -108.80M | -93.69M | -84.29M | -86.26M | -64.53M | -39.98M | -24.48M | -34.58M | -41.06M | -42.31M | -27.09M | -32.86M | -10.80M |
| EBITDA Ratio | -13,576.74% | -71,341.01% | -29,179.87% | -733.56% | 53.85% | -157.84% | -146.82% | -162.67% | 8.89% | -365.72% | -4,696.89% | -9,018.37% | -6,156.84% | -1,939.67% | -832.49% | -256.94% | -127.18% | -61.03% | -33.09% | -58.12% | -95.86% | -120.21% | -8.86% | -227.24% | -229.79% |
| Operating Income | -171.75M | -100.76M | -87.09M | -178.79M | 141.45M | -103.28M | -136.68M | -137.16M | 1.47M | -100.37M | -102.37M | -108.42M | -114.10M | -95.72M | -89.96M | -96.54M | -74.95M | -55.23M | -36.12M | -47.45M | -62.59M | -62.89M | -43.64M | -35.48M | -12.80M |
| Operating Income Ratio | -14,264.95% | -72,489.21% | -29,224.83% | -745.09% | 43.92% | -163.39% | -151.30% | -164.58% | 1.13% | -439.16% | -4,607.16% | -9,955.46% | -6,170.63% | -1,950.24% | -840.71% | -298.68% | -149.56% | -75.87% | -47.73% | -76.86% | -146.12% | -178.67% | -14.28% | -245.37% | -272.34% |
| Total Other Income/Expenses | -5.37M | -1.18M | -668.00K | -10.77M | -17.33M | -17.27M | -5.03M | -4.27M | -6.15M | 2.00K | -1.76M | -1.80M | -2.12M | -6.08M | -3.46M | -349.00K | 3.72M | 801.00K | -77.00K | 282.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -177.12M | -101.94M | -87.76M | -58.57M | 124.12M | -120.55M | -141.71M | -141.43M | -4.68M | -100.36M | -104.13M | -110.21M | -116.22M | -101.80M | -93.42M | -96.88M | -71.23M | 54.43M | 39.20M | -46.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -14,710.88% | -73,341.01% | -29,448.99% | -244.11% | 38.54% | -190.71% | -156.87% | -169.71% | -3.60% | -439.15% | -4,686.14% | -10,120.39% | -6,285.29% | -2,074.19% | -873.07% | -299.76% | -142.13% | 74.77% | 51.79% | -74.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.18M | 510.00K | 11.61M | -6.01M | 3.51M | -12.66M | 4.51M | 6.00M | -70.00K | -833.00K | -1.97M | -2.36M | -26.00K | -102.00K | -19.68M | -16.16M | -119.00K | 119.00K | -282.00K | 1.61M | -3.22M | -8.47M | -9.48M | -300.00K |
| Net Income | -177.12M | -103.13M | -88.27M | -70.18M | 130.13M | -120.55M | -129.05M | -141.43M | -4.68M | -100.29M | -104.13M | -110.21M | -116.22M | -101.78M | -82.78M | -76.86M | -58.79M | -54.31M | -36.32M | -47.17M | -64.20M | -59.67M | -35.17M | -25.99M | -12.50M |
| Net Income Ratio | -14,710.88% | -74,192.81% | -29,620.13% | -292.49% | 40.40% | -190.71% | -142.86% | -169.71% | -3.60% | -438.85% | -4,686.14% | -10,120.39% | -6,285.29% | -2,073.66% | -773.64% | -237.80% | -117.31% | -74.61% | -47.98% | -76.40% | -149.86% | -169.52% | -11.51% | -179.78% | -265.96% |
| EPS | -0.80 | -0.62 | -0.61 | -0.63 | 1.23 | -1.14 | -1.23 | -1.36 | -0.05 | -1.31 | -1.42 | -1.58 | -2.39 | -2.35 | -3.98 | -3.93 | -4.12 | -5.68 | -3.97 | -5.21 | -7.91 | -7.99 | -4.90 | -4.37 | -3.57 |
| EPS Diluted | -0.80 | -0.62 | -0.61 | -0.63 | 1.11 | -1.14 | -1.23 | -1.36 | -0.05 | -1.31 | -1.42 | -1.58 | -2.39 | -2.35 | -3.98 | -3.93 | -4.12 | -5.68 | -3.97 | -5.21 | -7.91 | -7.99 | -4.90 | -4.37 | -3.57 |
| Weighted Avg Shares Out | 221.13M | 165.73M | 145.65M | 110.84M | 106.22M | 105.74M | 105.12M | 103.86M | 103.59M | 76.35M | 73.30M | 69.96M | 48.68M | 43.26M | 20.78M | 19.54M | 14.26M | 9.55M | 9.14M | 9.05M | 8.12M | 7.47M | 7.17M | 5.95M | 3.50M |
| Weighted Avg Shares Out (Dil) | 221.13M | 165.73M | 145.65M | 110.84M | 116.75M | 105.83M | 105.24M | 103.86M | 103.59M | 76.35M | 73.30M | 69.96M | 48.68M | 43.26M | 20.78M | 19.54M | 14.26M | 9.55M | 9.14M | 9.05M | 8.12M | 7.47M | 7.17M | 5.95M | 3.50M |
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease
Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP)
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific Sessions of the American Diabetes Association being held June 21 - 24, 2024...
Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two Decades
NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, announced today that it has been selected by Lexicon Pharmaceuticals, Inc. to help advance PROGRESS, a Phase 2b study of LX9211...
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference. Jeff Wade, Lexicon's president and chief financial officer and Craig Granowitz, M.D., Ph.D., Lexicon's senior vice...
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1 Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon's president and chief financial officer, will make a company presentation...
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q1 2024 Earnings Conference Call May 2, 2024 5:00 PM ET Company Participants Lisa DeFrancesco - Head of Investor Relations and Strategy Lonnel Coats - Chief Executive Officer and Director Jeffrey Wade - President and...
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.17 per share a year ago.
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Commercial launch of INPEFA ® (sotagliflozin) for Heart Failure continues to progress
Source: https://incomestatements.info
Category: Stock Reports